MedTrace Logo

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

NCT02851589 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-08-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Conditions

Interventions

BIOLOGICAL

PCAR-019 (anti-CD19 CAR-T cells)

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xingbing Wang, Ph.D. · Anhui Provincial Hospital

  • Xin Liu, Ph.D. · Anhui Provincial Hospital

  • Lin Yang, Ph.D. · PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-11-30
Completion
2019-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02851589 on ClinicalTrials.gov